Appoints David Johnson as COO effective July 1, 2024

Vera Therapeutics, Inc.

David Johnson named COO; previously Chief Commercial Officer at Global Blood Therapeutics.
Annual base salary of $500,000; eligible for bonus up to 40% of base salary.
Granted option to purchase 160,000 shares at $36.29, vesting over 4 years.
Severance: 9 months salary without change in control; 12 months with change in control.
Johnson also receives up to $10,000 reimbursement for legal fees related to offer letter.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Johnson

Chief Operating Officer

VERA · Vera Therapeutics, Inc.

Effective: 2024-07-01
Filed: July 2, 2024, 7:59 PM ET

On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Johnson was appointed as Chief Operating Officer at Vera Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024

View on SEC.gov

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-174318

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.